The Effect of Luteinizing Hormone (LH) Supplementation Following Gonadotropin-releasing Hormone (GnRH) Antagonist Administration in Advanced Reproductive Ageing Women Undergoing IVF and Embryo Transfer (IVF/ET)
To explore whether recombinant LH (rLH) supplementation (Leuveris) to recombinant follicle stimulating hormone (rFSH) following GnRH antagonist treatment has an advantage in infertile women with advanced reproductive ageing undergoing IVF-ET.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
- Pregnancy rate [ Time Frame: Starting February 2010 ] [ Designated as safety issue: No ]
- Fertilization rate [ Time Frame: Starting February 2010 till April 2013 ] [ Designated as safety issue: No ]
|Study Start Date:||February 2010|
|Study Completion Date:||April 2013|
|Primary Completion Date:||March 2012 (Final data collection date for primary outcome measure)|
Experimental: 60 infertile women
Candidates for IVF-ET treatment
All recruited women will be treated similarly employing the recombinant FSH and the fixed GnRH antagonist. Concomitantly, on the same day of the antagonist administration r-LH will be administered daily and continued until human chorionic gonadotropin (hCG) day.
No Intervention: control